Saturday 17 October 2026 Export EVO’s income statement to Excel — free account

Evotec AG

EVO Healthcare Drug Manufacturers Specialty & Generic

Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

1.38 0.04 −2.82%

Follow EVO

Alert me

Market cap: $504.4M
P/E: 0.0×
Fwd P/E: −6.9×
Dividend yield: —
F-score: 5/9
Altman Z: 0.64
Beneish M: −2.62
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 5.15%

Capital & Financial Ratios $m

Market Cap 504.36

Revenue 864.62

Net Income (227.93)

Free Cash Flow (200.23)

Net Debt 11.95

Current Ratio 2.33

Debt/Equity 0.72

P/E ratio 0.00

Fwd P/E (6.94)

P/S ratio 0.57

P/B ratio 0.63

Past 5Y EPS Growth —

This Y EPS Growth (112.89%)

Next Y EPS Growth 74.08%

Next Y revenue growth (11.36%)

Next 5Y EPS Growth 84.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.11%

10-year low 10-year high

P/B against its own 10 years 0.11%

10-year low 10-year high

EV/Sales against its own 10 years 0.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	0.02	0.02
2018	0.14	0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
2017	0.14	0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
2016	0.17	0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	654	429	539	541
Receivables	194	171	197	155
Inventory	33	34	33	45
Other	41	54	55	60
	977	738	863	847

	2023	2024	2025	Q'26
Payables	145	93	73	57
ST’ Debt	—	—	118	72
Other	340	267	209	219
	503	373	416	363

Compound Annual Growth %

	10y	5y	3y
Sales	20.19%	9.28%	4.05%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	16.05%	2.20%	(9.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	183	—	—	—	—
’25	211	194	192	295	892
’24	227	196	203	236	862
’23	—	186	214	—	846
’22	185	183	175	249	792
’21	160	167	188	216	731
’20	132	123	151	166	572

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(125)	—	—	—
’25	(34)	28	(79)	75	(10)
’24	(52)	(54)	45	81	20
’23	—	(6)	23	—	39
’22	71	185	(18)	(24)	214
’21	3	47	23	72	145
’20	30	(38)	32	27	51

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	(137)	—	—	—
’25	(56)	(1)	(106)	60	(104)
’24	(94)	(96)	13	56	(121)
’23	—	(120)	(27)	—	(194)
’22	23	146	(89)	(57)	23
’21	(41)	3	(7)	49	4
’20	12	(51)	(1)	(22)	(62)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	—	—	—	—
’25	(0.09)	(0.14)	(0.14)	0.04	(0.33)
’24	(0.06)	(0.29)	(0.12)	(0.12)	(0.60)
’23	—	(0.05)	(0.12)	—	(0.26)
’22	(0.23)	(0.08)	(0.13)	(0.07)	(0.52)
’21	0.19	0.22	0.48	(0.13)	0.77
’20	0.06	(0.04)	0.00	0.00	0.02

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.64	3.63	7.37	10.13	10.11	17.07	7.80	7.94	2.85	2.84	Analyst estimates 2026–2028 Powerpack
	High	3.89	13.21	13.13	14.88	18.58	26.57	23.63	13.49	11.67	4.80
People
People	Employees	1,238	2,178	2,617	3,030	3,572	4,198	4,952	5,061	4,827	4,553
	Revenue/emp, $m	0.15	0.13	0.17	0.17	0.16	0.17	0.16	0.17	0.18	0.20
Income, $m
Income, $m	Revenue	182	291	443	500	572	731	792	846	862	892
	Gross margin, %	35.59	32.05	29.84	29.77	25.10	24.52	23.16	22.40	14.41	14.49
	EBT	36	30	85	63	29	280	(162)	(87)	(210)	(98)
	EBT margin, %	20.03	10.22	19.18	12.67	5.15	38.34	(20.49)	(10.31)	(24.34)	(11.01)
	Net income	30	27	99	42	7	255	(185)	(91)	(212)	(117)
	Depreciation	14	25	37	56	64	83	88	101	110	113
Per share, $
Per share, $	Revenue	0.69	1.00	1.50	1.67	1.86	2.20	2.24	2.39	2.43	2.51
	Earnings	0.11	0.10	0.34	0.14	0.02	0.76	(0.52)	(0.26)	(0.60)	(0.33)
	Cash flow	0.28	0.04	0.63	0.16	0.17	0.43	0.61	0.11	0.06	(0.03)
	Capex	(0.04)	(0.07)	(0.11)	(0.12)	(0.37)	(0.42)	(0.54)	(0.66)	(0.40)	(0.26)
	Free cash flow	0.24	(0.02)	0.51	0.04	(0.20)	0.01	0.06	(0.55)	(0.34)	(0.29)
	Book value	0.89	1.29	1.70	1.78	2.69	4.90	3.54	3.43	2.91	2.59
	Shares, m	265	290	295	299	308	333	353	354	355	355
Valuation, ×
Valuation, ×	P/E	35.39	91.00	30.41	92.98	1,048.57	30.94	0.00	0.00	0.00	0.00
	P/S	5.93	8.16	6.63	7.70	9.86	10.81	3.64	4.90	1.71	1.23
	P/B	4.56	6.33	5.85	7.20	6.83	4.85	2.30	3.25	1.43	1.19
	EV/Sales	5.33	8.54	6.53	7.98	9.85	10.23	3.34	4.28	1.90	1.19
	EV/FCF	15.29	(355.12)	19.17	363.59	(89.05)	2,795.22	121.73	(11.96)	(13.52)	(10.25)
Cash, $m
Cash, $m	Operating cash flow	75	12	185	47	51	145	214	39	20	(10)
	Capex	(11)	(19)	(33)	(36)	(113)	(141)	(191)	(233)	(141)	(93)
	Free cash flow	63	(7)	152	12	(62)	4	23	(194)	(121)	(104)
Balance, $m
Balance, $m	Working capital	106	(74)	63	325	514	919	775	475	365	447
	Total debt	32	214	133	503	545	590	518	516	425	508
	Net debt	(108)	111	(44)	144	(5)	(426)	(239)	(137)	(4)	(31)
	Shareholders’ equity	237	375	502	534	826	1,630	1,251	1,212	1,031	921
Returns, %
Returns, %	ROA	8.59	4.80	11.94	3.82	0.48	11.82	(7.37)	(3.77)	(9.41)	(5.84)
	ROIC	16.84	5.45	12.48	6.46	4.22	2.52	1.36	(2.99)	(9.39)	(4.47)
	ROE	13.71	8.96	22.68	8.23	1.05	20.77	(12.85)	(7.37)	(18.92)	(12.00)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COLL Collegium Pharmaceutical, Inc.	$754.6M	15.2×	12.5×	+6.32% (above 0%: growing)	n/m	−2.14% (below 0%: shrinking)	55.18%	1.85%	Compare
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
Median of peers	$487.2M	15.2×	—	+22.73%	—	+36.02%	56.87%	(7.37%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Evotec AG (EVO) key facts

Strength: Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024.
Evotec AG (EVO) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, EVO traded at $1.38, a market capitalization of $504.4 million.
Return on equity was −12.0% and debt-to-equity 0.72.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.64 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.